AELIX Therapeutics
Edit

AELIX Therapeutics

http://www.aelixtherapeutics.com/
Last activity: 16.09.2021
Active
Categories: AdTechBioTechDevelopmentHumanITResearchService
AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, the Catalan public-private consortium conducting cutting-edge research in this field. AELIX holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen.
Followers
184
Followers
1.49K
Mentions
17
Location: Spain, Catalonia, Barcelona
Employees: 11-50
Total raised: $12.49M
Founded date: 2014
Twitter
LinkedIn
Email

Investors 2

Funding Rounds 1

DateSeriesAmountInvestors
11.01.2016Series A$12.49M-

Mentions in press and media 17

DateTitleDescription
16.09.2021El CDTI invierte junto a Caixa Innvierte Start e Ysios BioFund II Innvierte en Aelix Therapeutics16/09/2021 Nota de prensa EL CDTI INVIERTE JUNTO A CAIXA INNVIERTE START E YSIOS BIOFUND II INNVIERTE EN AELIX THERAPEUTICS. El CDTI, a través de su programa Innvierte, conjuntamente con las gestoras de capital riesgo (venture capital) C...
11.03.2021Ani Phar­ma picks up gener­ic play­er for a cool $210M, tur­bocharg­ing its man­u­fac­tur­ing and R&D wingsThe FDA is continuing its review of cancer drugs that have won accelerated approvals with three days of advisory committee meetings in late April to investigate different indications for Roche’s Tecentriq, Merck’s Keytruda and Bristol Myers...
11.03.2021Ani Phar­ma picks up gener­ic play­er for a cool $210M, tur­bocharg­ing its man­u­fac­tur­ing and R&D wingsCon­tract man­u­fac­tur­ing work has grown at a rapid clip the past year giv­en de­mand caused in part by Covid-19. Big play­ers are dou­bling down on their pro­duc­tion foot­prints, and even small play­ers are tak­ing big swings to get in­...
11.03.2021FDA de­lays Kad­mon’s pri­or­i­ty re­view as ap­par­ent clam­p­down con­tin­uesKad­mon Hold­ings just lost their pri­or­i­ty re­view. The im­munol­o­gy biotech an­nounced Wednes­day that the FDA has pushed back the de­ci­sion date for their graft-ver­sus-host dis­ease drug belu­mo­sudil by three months, af­ter the age...
11.03.2021Prometheus up­sizes IPO by 33% ahead of pric­ing; Hu­mani­gen se­cures loan of up to $80M to de­vel­op lenzilum­abEd­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here. Af­ter ini­tial­ly pen­cil­ing in a $125 mil­lion IPO, Prometheus is up­siz­ing that goal a cou­ple dozen mil­lion ...
11.03.2021In race for in vi­vo sick­le cell cure, In­tel­lia un­veils (very) ear­ly proof-of-con­ceptVer­tex and CRISPR Ther­a­peu­tics have shown they can use the gene edit­ing tool to cure, for at least a cou­ple years, a hand­ful of pa­tients with sick­le cell dis­ease and are now en­ter­ing late-stage de­vel­op­ment. It’s a ma­jor ad­v...
11.03.2021Gilead part­ner touts an ear­ly snap­shot of its HIV vac­cine ap­proach to a cure — but there's a long path aheadMore than 2 years af­ter al­ly­ing it­self with HIV gi­ant Gilead on a com­bo ap­proach to a pos­si­ble cure, the small Span­ish biotech Aelix Ther­a­peu­tics is out with some ear­ly pos­i­tive da­ta on its vac­cine pro­gram. And they’re us...
11.03.2021Covid-19 roundup: Pfiz­er/BioN­Tech re­lease re­al-world ev­i­dence of vac­cine ef­fi­ca­cy; EMA gives J&J shot thumbs upWith their Covid-19 vac­cine hav­ing been au­tho­rized for rough­ly three months, Pfiz­er and BioN­Tech have re­leased a look in­to some re­al-world ev­i­dence re­gard­ing the shot’s ef­fec­tive­ness in Is­rael. Ac­cord­ing to their analy­s...
11.03.2021Alex Gorsky earned a whop­ping $29.6M in 2020 as drug­mak­er piv­ot­ed around Covid-19 vac­cine R&DIn near­ly nine years helm­ing J&J, CEO Alex Gorsky has watched his drug­mak­er morph in­to the sin­gle largest com­pa­ny in bio­phar­ma. But 2020 was a year like no oth­er, re­quir­ing J&J’s mas­sive ma­chin­ery to piv­ot around de...
11.03.2021Covid-19 man­u­fac­tur­ing roundup: Biden dou­bles down on vac­ci­na­tion plan with 100M-dose or­der; BioN­Tech, Pfiz­er ready to in­crease man­u­fac­tur­ing; J&J ex­pe­ri­ences de­liv­ery woes...With head­lines around the globe fo­cused on var­i­ous hitch­es in the glob­al sup­ply chain for Covid vac­cines, Pres­i­dent Joe Biden is tak­ing out an in­sur­ance pol­i­cy of sorts to help guar­an­tee his promise to rapid­ly ex­pand ac­c...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In